In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DNA Therapeutics SA

Division of Onxeo SA

Latest From DNA Therapeutics SA

Onxeo Seeks Partner For Its Expanding Oncology Pipeline

Onxeo, a biotech company developing drugs for orphan oncology indications, plans to secure financial backing from a pharma partner for its lead product Livatag based on impending Phase III results, CEO Judith Greciet told Scrip in an interview.

Companies ImmunoOncology

Deals In Depth: February 2016

Baxalta signed its first major CART deal, with Precision BioSciences; Stryker spent over $4bn to acquire Sage and Physio-Control. Coherus BioSciences and Kinetic Concepts/KCI USA completed big debt offerings.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Onxeo SA
  • Senior Management
  • Jiang-Sheng Sun, PhD, CEO
    Marie Dutriex, PhD, Acting CSO
    Michel Marty, MD, Acting CMO
    Michel Hubert, Acting CBO
  • Contact Info
  • DNA Therapeutics SA
    4 rue Pierre Fontane
    Evry Cedex, 91058